The UK government’s announcement of a 26.5% VPAS rate for 2023 “will make some products lossmaking,” the BGMA has cautioned, expressing serious concerns for the branded generics and biosimilars sector as it points to the risk of shortages, higher prices and fewer launches in the UK.
A newly-revealed rebate rate that will apply to UK branded generics and biosimilars suppliers in 2023 threatens to push products out of the market by making them unprofitable, the British Generic Manufacturers Association has warned, raising the potential for shortages, higher prices due to reduced competition, and a reduction in new launches in the UK market.
The Voluntary Scheme for Branded Medicines Pricing and Access, or VPAS, was introduced in 2019 and aims to limit National...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
